NEW YORK, June 7, 2017 /PRNewswire/ --
On Tuesday, June 06, 2017, the NASDAQ Compositeended the trading session at 6,275.06, down 0.33%; the Dow Jones Industrial Average edged 0.23% lower, to finish at 21,136.23; and the S&P 500 closed at 2,429.33, slightly dropping 0.28%. Losses were broad based as six out of nine sectors ended the
On Tuesday, shares in Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc. recorded a trading volume of 318,881 shares. The stock ended at $20.70, climbing 1.72% from the last trading session. The Company's shares have gained 26.22% over the previous three months and 34.42% on an YTD basis. The stock is trading above its 200-day moving average by 30.74%. Furthermore, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have a Relative Strength Index (RSI) of 43.04.
On May 19th, 2017, research firm Raymond James initiated a 'Strong Buy' rating on the Company's stock. Sign up and read the free research report on PRTK at:
Shares in Needham, Massachusetts headquartered Verastem Inc. recorded a trading volume of 162,303 shares. The stock ended at $2.17, rising 0.93% from the last trading session. The Company's shares have gained 5.34% in the last one month, 82.35% over the previous three months, and 93.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.36% and 47.50%, respectively. Furthermore, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have a Relative Strength Index (RSI) of 48.14. The complimentary research report on VSTM can be downloaded at:
At the close of trading on Tuesday, shares in Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc. rose 1.93%, ending the day at $71.28. The stock recorded a trading volume of 1.23 million shares, which was above its three months average volume of 1.11 million shares. The Company's shares have advanced 29.44% in the last one month, 42.73% in the previous three months, and 90.38% since the start of this year. The stock is trading 24.61% and 38.13% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 62.98.
On May 15th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $95 a share to $110 a share. Register for free on DailyStockTracker.com and access the latest report on ALNY at:
Albany Molecular Research
Albany, New York headquartered Albany Molecular Research Inc.'s shares ended the day 8.90% higher at $21.53. A total volume of 20.24 million shares was traded, which was above their three months average volume of 833,460 shares. The stock has gained 38.01% in the last month, 56.81% over the previous three months, and 14.77% on an YTD basis. The Company's shares are trading 32.35% above their 50-day moving average and 30.93% above their 200-day moving average. Additionally, shares of Albany Molecular Research, which provides integrated drug discovery, development, and manufacturing services primarily in the US, Europe, and Asia, have an RSI of 78.00.
On June 06th, 2017, research firm William Blair downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Get free access to your research report on AMRI at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207) 331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Do fad diets really work? Here are some disadvantages and side-effects of going on a fad diet. ...
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...View All